Johnson And Johnson

Adjusted profit was $2.42 a share, surpassing Wall Street's average estimate of $2.19. Pharmaceutical revenue rose almost 5 per cent, exceeding expectations by more than $400 million

J&J recently garnered support from more than 75 per cent of baby powder claimants for an out-of-court deal that includes claims that the talc-based version caused ovarian and other gynecological cance

The increase would boost the size of the settlement to more than $9 billion paid over 25 years

J&J now faces more than 61,000 suits blaming talc for different types of cancers. Many of the cases have been consolidated before a federal judge in New Jersey

Nigeria's regulator recalled a batch of Benylin syrup last Wednesday, having found a high level of diethylene glycol in the product during routine testing

Sales of its blockbuster psoriasis drug Stelara were flat at $2.45 billion in the first quarter, while sales of Darzalex jumped about 19% to $2.69 billion

Shipp took over the case in February 2023, after the retirement of former Chief District Judge Freda Wolfson, who had overseen the litigation since 2016

Biocon said that the U.S. FDA has accepted the Biologics License Application (BLA) for Bmab 1200 (bUstekinumab) for review under the 351(k) pathway

Shares of J&J fell slightly as trading began Monday morning in New York, but closed with a 0.25 per cent gain at $161.53. The stock fell 11 per cent last year

(Reuters) - Johnson & Johnson and Indian drugmaker Lupin will supply their versions of the tuberculosis drug bedaquiline at a significantly cheaper price in low- and middle-income countries, a global anti-tuberculosis group said on Wednesday.

J&J shares dropped as much as 3.4% in post-market trading following the ruling. The company vowed to appeal Judge Kaplan's ruling

Pharmaceutical industry says the drug price negotiation program that is part of President Joe Biden's IRA will curtail profits and compel them to pull back on developing groundbreaking new treatment

US Bankruptcy Judge Michael Kaplan said Thursday the company won't have to go to trial over any talc lawsuits for at least 60 days, but new lawsuits can be filed

The company says it has a deal backed by as many as 80,000 claimants, which should be enough to meet a key legal threshold to push a settlement worth $8.9 billion through bankruptcy

Johnson & Johnson beat first-quarter expectations, as growth in the health care giant's home market helped counter another revenue hit overseas from a strong dollar. The health care giant booked a USD 68 million loss on a one-time charge in the quarter, and revenue grew more than 5 per cent to USD 24.75 billion, which was better than anticipated. Adjusted earnings totalled USD 2.68 per share, topping Wall Street projections for per-share earnings of USD 2.50, according to a survey by FactSet. Johnson & Johnson sells prescription drugs and medical devices. It is splitting off its consumer health business, which includes well-known products like BandAids. The company expects to complete the separation this year. Sales in the US grew nearly 10 per cent to USD 12.52 billion in the quarter, while international sales climbed nearly 2 per cent. A strong US dollar can affect sales for companies that do a lot of international business. They have to convert those sales into dollars when

The benchmark 10-year Treasury note reversed early declines to rise for the fourth straight day, while big technology and growth names like Apple Inc, Amazon.com and Nvidia Corp cut back gains

The company said it expects some impact of inflation to ease next year but higher costs of inventory manufactured in 2022 could weigh on 2023 profit

Maharashtra's Food and Drugs Administration (FDA) on Friday cancelled the baby powder manufacturing licence of Johnson & Johnson Pvt Ltd "in the interest of public health at large". In a release, the state government agency said the company's product, Johnson's Baby Powder, may affect the skin of newborn babies. Samples of the powder for babies did not conform to standard pH value during a laboratory test, the regulator said. The release said the action was taken after Kolkata-based Central Drugs Laboratory's conclusive report that concludes "the sample does not conform to IS 5339:2004 with respect to the test for pH. According to the release, FDA had drawn samples of Johnson's Baby Powder from Pune and Nashik for quality check purposes. The government analyst had declared the samples as "not of the standard quality" as they do not comply with IS 5339:2004 specification for skin powder for infants in the test pH, it said. Thereafter, FDA issued a show-cause notice to ...

Johnson and Johnson (J&J) has been facing several thousand lawsuits from women who claim that they developed ovarian cancer after using the product

After 38,000 serious allegations, Johnson and Johnson's talc-based baby powder will stop international sales from 2023. The product has already been discontinued in the US and Canada